PEGylation of Interferon-β-1a
@article{Kieseier2012PEGylationOI, title={PEGylation of Interferon-β-1a}, author={B. Kieseier and P. Calabresi}, journal={CNS Drugs}, year={2012}, volume={26}, pages={205-214} }
Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic… CONTINUE READING
42 Citations
An update on the evidence base for peginterferon β1a in the treatment of relapsing–remitting multiple sclerosis
- Medicine
- Therapeutic advances in neurological disorders
- 2016
- 7
Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial
- Medicine
- Therapeutic advances in neurological disorders
- 2016
- 25
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
- Medicine
- British journal of clinical pharmacology
- 2016
- 21
Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
- Medicine
- Multiple sclerosis and related disorders
- 2018
- 1
Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
- Medicine
- Journal of clinical pharmacology
- 2015
- 3
Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
- Medicine
- CNS Drugs
- 2015
- 14
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
- Medicine
- Degenerative neurological and neuromuscular disease
- 2017
- 5
- PDF
Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties
- Medicine
- PloS one
- 2014
- 27
- PDF
Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU
- Medicine
- 2015
- 1
Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?
- Medicine
- Drug discovery today
- 2020
References
SHOWING 1-10 OF 71 REFERENCES
Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients
- Medicine
- Anti-cancer drugs
- 2003
- 62
Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients
- Medicine
- Expert opinion on pharmacotherapy
- 2001
- 13
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
- Chemistry, Medicine
- Bioconjugate chemistry
- 2006
- 130
Pegylation: a novel process for modifying pharmacokinetics.
- Medicine, Chemistry
- Clinical pharmacokinetics
- 2001
- 701
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
- Medicine
- Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
- 2010
- 32
Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
- Medicine
- International journal of nanomedicine
- 2007
- 11
PEG conjugates in clinical development or use as anticancer agents: an overview.
- Chemistry, Medicine
- Advanced drug delivery reviews
- 2009
- 361
Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.
- Medicine
- European journal of cancer
- 2010
- 15